News | Regulatory news 2024-06-26 Redwood Pharma provides a new update regarding divestment of company assets Regulatory 2024-06-12 Redwood Pharma provides an update on the process for divesting the company’s assets 2024-05-23 Redwood Pharma provides an update on the company’s future Regulatory 2024-05-08 Redwood Pharma’s product RP501 attracted a lot of interest at ARVO in Seattle 2024-05-07 Two international companies begin due diligence on Redwood Pharma’s product RP501 ahead of potential commercial agreements 2024-05-06 Redwood Pharma’s board subscribes to units in the ongoing new issue 2024-02-28 Redwood Pharma’s innovative dry eye treatment to be presented at ARVO in Seattle 2023 2023-12-19 Redwood Pharma to participate in the JP Morgan Healthcare Conference 2023-11-30 Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ) Regulatory 2023-11-22 Redwood Pharma to participate in the NLS Days partner conference in Copenhagen 2023-10-19 Redwood Pharma to participate in the BIO-Europe partnering conference in Munich 2023-05-31 Redwood Pharma presents positive results from a clinical study with RP501 against dry eye Regulatory 2023-03-17 Redwood Pharma completes recruitment for clinical trial with RP501 for dry eye 2023-01-24 Redwood Pharma takes important steps towards the commercial production of its dry eye product 2022 2022-12-15 Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501 Regulatory 2022-10-03 Redwood Pharma to present at AKTIEPORTFÖLJEN LIVE SVERIGE in Stockholm on 11th of Oct. 2022 at 14:45 2022-09-08 Redwood Pharma to present at BioStock Investor Meeting in Stockholm on 14th of Sep. 2022 2022-06-03 Redwood Pharma CEO Martin Vidaeus to present at BioStock Life Science Spring Summit 2022-05-16 CEO Presentation at the Annual General Meeting of Redwood Pharma on May 10, 2022 2022-05-10 Redwood Pharma AB (publ) Quarterly report January–March 2022 Regulatory 2022-05-05 The first patient has started Redwood Pharma’s RP501 treatment for dry eye 2022-05-02 Redwood Pharma to present at the BioStock Life Science Summit in Lund and Stockholm on 8-9 June 2022 2022-03-28 Redwood Pharma receives approval from the Austrian drug authority to start RP501 clinical trial Regulatory 2022-03-25 Dry Eye FACTS: first line therapies are tried by nearly all sufferers 2022-03-11 Breaking ground with a novel first line dry eye therapy 2022-02-16 Redwood Pharma AB (publ) Year-end report 2021 Regulatory 2022-02-07 Redwood Pharma receives approval from an Austrian ethics committee for start of a clinical trial of RP501 2022-01-24 Redwood Pharma to attend the ARVO annual meeting and BIO-Europe (Fall) in 2022 2021 2021-12-16 RP501 represents an extension into the medical technology arena for Redwood Pharma 2021-10-25 Accelerating development of RP501 first-line therapy for dry eye disease Regulatory 2021-08-27 Redwood Pharma AB (publ) Quarterly report January–June 2021 Regulatory 2021-03-22 Phase II results published in medical journal and Redwood Pharma to present poster at medical meeting 2021-02-11 Redwood Pharma will receive approximately SEK 34.2 million through a heavily oversubscribed rights issue Regulatory 2021-01-20 Redwood Pharma to provide digital presentations in connection with the rights issue 2021-01-18 Redwood Pharma announces intention to move to Nasdaq First North Growth Market stock exchange Regulatory 2020 2020-12-29 Supplementary analyses to topline Phase II results reveal additional RP101 clinical strengths 2020-10-12 Redwood Pharma to present at Aktiespararnas Stora Aktiedagen Digitalt in Stockholm on November 30, 2020 2020-10-09 RP501: Redwood Pharma makes official name for mild dry eye therapeutic development program 2020-09-08 Redwood Pharma launches new development program for mild dry eye based on its proprietary IntelliGel platform Regulatory 2020-08-28 Quarterly Report January–June 2020 Regulatory 2020-07-23 New patent for the use of estrogens in the treatment of DED to be issued in the US Regulatory 2020-06-22 Video interview with CEO Martin Vidaeus – Positive Redwood Pharma status 2020-06-18 Redwood Pharma secures bridge financing and issues warrants Regulatory 2020-05-18 Redwood Pharma will receive approximately SEK 2.1 million 2020-05-11 Quarterly report January – March 2020 Regulatory 2020-03-12 Live Webcast of the announcement of RP101 Phase II clinical results 2020-03-12 RP101 Phase II clinical results Regulatory 2020-02-28 Redwood Pharma to present at BIO-Europe Spring 2020-02-14 Redwood Pharma AB (publ) Year-end report 2019 Regulatory 2020-02-10 Patent to be granted in China regarding IntelliGel Regulatory 2019 2019-12-05 Video presentation (ENG) of clinical status of RP101 by CEO Martin Vidaeus 2019-11-27 Redwood Pharma arranging partnering meetings during JPMorgan Healthcare Conference 2020 in San Francisco 2019-11-19 Redwood Pharma AB Quarterly Report January – September 2019 Regulatory 2019-11-18 Redwood Pharma to present at BioStock Live in Stockholm on December 3, 2019 2019-11-12 Last patient completes treatment in RP101 Phase II clinical trial Regulatory 2019-10-25 Redwood Pharma to attend BIO-Europe Nov. 10-12 in Hamburg 2019-08-13 Redwood Pharma to present at BioStock Live in Stockholm on August 27, 2019 2019-08-05 Last patient recruited in Redwood Pharma Phase II trial Regulatory 2019-06-19 Update regarding financial situation Regulatory 2019-06-18 Update regarding RP101 Phase II trial Regulatory 2019-02-11 Redwood Pharma to Attend BIO-Europe 2019, Mar. 25 – 27 in Vienna for Partnering Discussions 2019-02-04 First patient treated in Redwood Pharma Phase II study Regulatory 2019-01-07 Redwood Pharma receives its third and last national approval Regulatory 2018 2018-12-14 Redwood Pharma receives approval from another drug authority – the Austrian Regulatory 2018-11-12 Redwood Pharma initiates clinical trial Regulatory 2018-10-02 New patent for IntelliGel on the way in the EU Regulatory 2018-09-18 Redwood Pharma to Attend BIO-Europe 2018, Nov. 5 – 7 in Copenhagen for Partnering Discussions 2018-09-10 Redwood Pharma to present at Nordic Life Science Days in Stockholm on September 11, 2018 2018-08-29 Interim Report January – June 2018 Regulatory 2018-08-21 Come meet us when Redwood Pharma presents 2018-07-09 Redwood Pharma has submitted an application for the start of clinical trial Regulatory 2018-06-13 Video Presentation (ENG) by Redwood Pharma June 11, 2018 2018-05-30 Redwood Pharma to present at NLSDays in Stockholm, Sep. 10-12, 2018 2018-04-26 Redwood Pharma’s new rights issue oversubscribed Regulatory 2018-03-15 Redwood Pharma to execute New Rights Issue and takes important step in securing further financing Regulatory 2018-03-08 Redwood Pharma acquires intellectual property rights Regulatory 2018-02-26 Asian Pharmaceutical Firm to Evaluate IntelliGel® Regulatory 2018-02-26 Positive meeting with Medical Products Agency prior to clinical Phase II trial Regulatory 2018-02-23 Additional US patent to be granted regarding IntelliGel Regulatory 2018-01-22 Redwood Pharma to Attend BIO-Europe 2018, Mar. 11 – 14 in Amsterdam for Partnering Discussions 2017 2017-12-04 Interview with CEO: Development throught toxicology and safety studies 2017-11-28 Redwood Pharma starts production of RP101 for clinical trials Regulatory 2017-11-20 Toxicology and Safety Studies are Successfully Completed Regulatory 2017-09-20 Redwood Pharma to Attend Bio-Europe 2017, Nov. 6 – 8 in Berlin for Partnering Discussions 2017-09-01 Redwood Pharma enters into agreement with CRO for clinical trial Regulatory 2017-06-02 Redwood Pharma begins production of active ingredient in RP101 for Phase II studies Regulatory 2017-03-15 Redwood Pharma initiates toxicological safety studies Regulatory 2017-03-02 New US patent approved Regulatory 2017-02-15 Redwood Pharma AB (publ) End of Year Report 2016 Regulatory 2017-02-13 Eye expert to support Redwood Pharma Regulatory 2017-01-16 Redwood Pharma has developed a process for manufacture of the drug RP101 for coming safety studies Regulatory 2016 2016-12-21 Development of Redwood Pharma’s RP101 ophthalmic therapy continues according to plan along with value-enhancing networking 2016-11-08 Redwood Pharma AB (publ) to present at Aktiespararna conference in Örebro on November 19, 2016 2016-10-07 Redwood Pharmas IntelliGel drug delivery platform demonstrates positive results in in vitro test 2016-09-20 Redwood Pharma AB appoints Ulf Björklund as Chief Medical Officer 2016-09-16 Market Trends Highlighted in Tear Film and Ocular Surface (TFOS) Conference in Montpellier Confirm Need for Redwood Pharmas Dry Eye Therapy 2016-08-30 Japanese patent granted for IntelliGel platform 2016-08-11 Redwood Pharma to present at French-Swedish Life Science Day 2016 2016-08-09 Redwood Pharma to attend leading conference on ocular tear film science 2016-07-11 Redwood Pharma attending OIS-ASRS Conference in San Francisco 2016-06-07 Redwood Pharma to Present at BIO 2016 in San Francisco 2016-02-23 Redwood Pharma raises SEK 6.6 million in private placement Regulatory 2015 2015-06-24 Redwood Pharma licenses novel hydrogel drug delivery technology from Broda Technologies Latest presentation Finwire interview Presentations Latest report Reports
